Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | CASP3 | P42574 | 1/20 | 0.56 |
| ▸ | AHR | P35869 | 1/20 | 0.50 |
| ▸ | CCNE2 | O96020 | 9/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.49 |
| ▸ | CDK2 | P24941 | 9/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | CDK4 | P11802 | 4/20 | 0.45 |
| ▸ | CCND1 | P24385 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15580925 | 1.00 | MAOA (0.61) | MAOAALDH1A1KDM4EHPGDGAA | |
| SCHEMBL29860722 | 1.00 | MAOA (0.61) | MAOAALDH1A1KDM4EHPGDGAA | |
| SCHEMBL705018 | 0.89 | MAOA (0.49) | MAOAALDH1A1KDM4EHPGDGAA | |
| SCHEMBL17580121 | 0.89 | MAOA (0.49) | MAOAALDH1A1KDM4EHPGDGAA | |
| SCHEMBL17590085 | 0.85 | MAOA (0.44) | MAOAALDH1A1KDM4EHPGDGAA | |
| SCHEMBL3828974 | 0.83 | MAOA (0.51) | MAOAALDH1A1KDM4EHPGDGAA | |
| SCHEMBL15444503 | 0.83 | MAOA (0.43) | MAOAALDH1A1KDM4EHPGDGAA | |
| SCHEMBL18328582 | 0.83 | CA1 (0.43) | MAOAALDH1A1KDM4EHPGDGAA | |
| SCHEMBL20334273 | 0.80 | MAOA (0.90) | MAOAALDH1A1KDM4EHPGDGAA | |
| SCHEMBL29986841 | 0.79 | MAOA (0.87) | MAOAALDH1A1KDM4EHPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 646 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3619195-B1 | NOVEL PROCESS TO PREPARE N-[2-[(1S)-1-(3-ETHOXY-4-METHOXYPHENYL)-2-(METHYLSULPHONYL) ETHYL]-1, 3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YL]ACETAMIDE | UNICHEM LAB LTD (IN) | 2025-07-23 | — | — | EP | claimed |
| US-12351555-B2 | Process for synthesizing apremilast | AMGEN INC. (US) | 2025-07-08 | — | — | US | claimed |
| CN-120042058-A | Surface treatment method for carbon fiber | 山东体育学院 | 2025-05-27 | — | — | CN | claimed |
| CN-119528790-A | Apremilast impurity and preparation method thereof | 南京百泽医药科技有限公司 | 2025-02-28 | — | — | CN | claimed |
| CN-118954498-A | Graphite composite material and preparation method and application thereof | 深圳市金牌新能源科技有限责任公司 | 2024-11-15 | — | — | CN | claimed |
| CN-118851979-A | Preparation method of apremilast | 潍坊市海欣药业有限公司 | 2024-10-29 | — | — | CN | claimed |
| CN-118834155-A | Preparation method of apremilast | 江苏知原药业股份有限公司 | 2024-10-25 | — | — | CN | claimed |
| CN-113121404-B | Synthesis method of apremilast | 江苏先声药业有限公司 | 2024-07-09 | — | — | CN | claimed |
| EP-4330230-A1 | PROCESS FOR SYNTHESIZING APREMILAST | AMGEN INC. (US) | 2024-03-06 | — | — | EP | claimed |
| CN-113896674-B | Synthesis method of apremilast | 深圳华中科技大学研究院 | 2023-10-27 | — | — | CN | claimed |
| CN-105622380-A | Preparation method of Apremilast and intermediate | NANJING ANYUAN BIO-PHARMACEUTICAL TECH CO LTD | 2016-06-01 | — | — | CN | claimed |
| EP-2420490-A1 | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of using and compositions thereof | CELGENE CORPORATION (US) | 2012-02-22 | — | — | EP | claimed |
| CN-101683334-A | (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof | CELGENE CORP | 2010-03-31 | — | — | CN | claimed |
| CN-1965823-A | Preparing methods of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione and its compound | CELGENE CORP (US) | 2007-05-23 | — | — | CN | claimed |
| US-20050192336-A1 | Treatment may include administration of a second active agent, including but not limited to, an anti-inflammatory agent, an immnunosuppressant, mycophenolate mofetil, a biologic agent, or a Cox-2 inhibitor | AMGEN INC. | 2005-09-01 | — | — | US | claimed |
| CN-1652772-A | (+) -2- [ 1- (3-ethoxy-4-methoxyphenyl) -2-methylsulfonylethyl ] -4-acetylaminoisoindoline-1, 3-dione, methods of use, and compositions thereof | CELGENE CORP (US) | 2005-08-10 | — | — | CN | claimed |
| EP-1485087-A1 | (+)-2- 1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | CELGENE CORPORATION (US) | 2004-12-15 | — | — | EP | claimed |
| US-20030187052-A1 | Controrlling concentration of tumor necrosis factor, phosphodiesterase inhibitor; controlling cell differentiation, proliferation; antiinflammatory agents; cardiovascular disorders | AMGEN INC. | 2003-10-02 | — | — | US | claimed |
| WO-2003080048-A1 | (-)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | CELGENE CORPORATION (US) | 2003-10-02 | — | — | WO | claimed |
| WO-2003080049-A1 | (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF | CELGENE CORPORATION (US) | 2003-10-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187052-A1 | Controrlling concentration of tumor necrosis factor, phosphodiesterase inhibitor; controlling cell differentiation, proliferation; antiinflammatory agents; cardiovascular disorders | PDE4A, PDE2A, PDE3A | MAOA 790/4885ALDH1A1 761/4885KDM4E 1755/4885 |
| US-20050192336-A1 | Treatment may include administration of a second active agent, including but not limited to, an anti-inflammatory agent, an immnunosuppressant, mycophenolate mofetil, a biologic agent, or a Cox-2 inhibitor | IL4, PTGER4, PDE4A | MAOA 941/4885ALDH1A1 450/4885KDM4E 1668/4885 |
| US-12351555-B2 | Process for synthesizing apremilast | TPMT, MAST1, NPEPPS | MAOA 717/4885ALDH1A1 33/4885KDM4E 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.